RenovoRx, Inc. (RNXT)
1.19
+0.07
(+6.25%)
USD |
NASDAQ |
Oct 15, 16:00
1.20
+0.01
(+0.84%)
After-Hours: 20:00
RenovoRx Cash from Operations (TTM) : -11.87M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -11.87M |
| March 31, 2026 | -11.30M |
| December 31, 2025 | -10.97M |
| September 30, 2025 | -10.38M |
| June 30, 2025 | -10.31M |
| March 31, 2025 | -10.30M |
| December 31, 2024 | -9.125M |
| September 30, 2024 | -8.748M |
| June 30, 2024 | -9.282M |
| March 31, 2024 | -9.756M |
| Date | Value |
|---|---|
| December 31, 2023 | -10.26M |
| September 30, 2023 | -9.886M |
| June 30, 2023 | -9.83M |
| March 31, 2023 | -9.42M |
| December 31, 2022 | -8.811M |
| September 30, 2022 | -9.688M |
| June 30, 2022 | -8.135M |
| March 31, 2022 | -7.021M |
| December 31, 2021 | -5.916M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Enanta Pharmaceuticals, Inc. | -35.32M |
| Travere Therapeutics, Inc. | 92.70M |
| REGENXBIO, Inc. | -246.67M |
| Krystal Biotech, Inc. | 272.34M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |